UnknownPhase 3

REduction of Post-Operative Urinary Retention With Tamsulosin Versus Placebo (REPOURT- P) Trial

350 participantsStarted 2021-07-30

Plain-language summary

The purpose of this study are to determine the efficacy of tamsulosin compared to placebo in reducing post-operative urinary retention and improving other clinical outcomes in people undergoing thoracic surgery.

Who can participate

Age range40 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male patients greater than the age of 40 and/or with type 2 diabetes undergoing pulmonary surgery who did not undergo straight or indwelling urinary catheterization intraoperatively.
✓. Male patients receiving a thoracic epidural analgesia undergoing pulmonary surgery who did not undergo straight or indwelling urinary catheterization intraoperatively

Exclusion criteria

✕. Active treatment of Benign Prostatic Hyperplasia (BPH)
✕. Hypersensitivity or allergy to tamsulosin HCL
✕. Active treatment with tamsulosin or other alpha-blocker or uses of tamsulosin/ other alpha-blocker within 3 weeks of enrollment date
✕. Active urinary tract infection
✕. History of urological disorder specified as urethral stricture, BPH, bladder or prostate malignancy
✕. History of urological surgery (Transurethral resection of the Prostate, Transurethral resection of the Bladder, Bladder suspension, prostatectomy)
✕. Underlying neurological disorders resulting in impaired bladder function
✕. Any known contraindication to the use of tamsulosin HCL

What they're measuring

Rate of post-operative urinary retention (POUR)

Timeframe: 0-24 hours

Trial details

NCT IDNCT04159077

SponsorMcMaster University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-31

Contact for this trial

Housne Begum, PhD

(905)522-1155 begumh@mcmaster.ca

View on ClinicalTrials.gov More Urinary Catheterization trials